Romidepsin Nanoparticle Delivery for Off-Target Toxicity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing HDAC inhibitors like romidepsin face challenges with toxicity, efficacy in combination therapies, and limited effectiveness in certain cancer types, particularly peripheral T cell lymphoma (PTCL), due to off-target effects and excessive toxicity when combined with chemotherapy.
Innovation Solution
Development of romidepsin encapsulated in nanoparticles, specifically poly(D,L-lactide)-PEG-methyl ether nanoparticles, to enhance targeted delivery and reduce off-target toxicity, allowing for combination with other therapeutics to improve efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If romidepsin is administered as a conventional HDAC inhibitor, then it can inhibit Class I and Class II HDACs to achieve anticancer effects, but it causes excessive toxicity and off-target effects that limit combination therapy
Solution Approach 1:
The patent segments the broad HDAC inhibition activity into selective Class I HDAC inhibition through nanoparticle delivery. The nanoparticle formulation enables romidepsin to selectively target and inhibit Class I HDACs (1, 2, 3, 8) while sparing Class II HDACs, thereby maintaining anticancer efficacy while reducing off-target toxicity that limits combination therapy
Solution Approach 2:
The nanoparticle acts as an intermediary delivery system that modifies romidepsin's pharmacokinetic and pharmacodynamic properties. This intermediary formulation controls drug release and enhances selective accumulation in tumor tissues, reducing systemic toxicity while maintaining reliable anticancer effects
2Reliability
If romidepsin is combined with chemotherapy to improve efficacy, then therapeutic outcomes may be enhanced, but off-target effects and excessive toxicity increase
Solution Approach 1:
The nanoparticle formulation creates local quality differences in drug distribution, concentrating romidepsin selectively at tumor sites while minimizing exposure to healthy tissues. This localized delivery enables safer combination therapy by reducing off-target effects that would otherwise limit the use of combination regimens
Solution Approach 2:
The patent converts the potential harm of combination therapy toxicity into benefit by using the nanoparticle to protect healthy tissues. The controlled delivery system allows combination therapy to proceed at doses that would be toxic in conventional form, transforming the limitation into an opportunity for enhanced efficacy
3Reliability
If HDAC inhibitors are used to maintain open chromatin structure and induce gene expression changes, then anticancer activity is achieved, but the broad inhibition of multiple HDAC classes causes toxicity
Solution Approach 1:
The nanoparticle delivery system segments the HDAC inhibition effect to selectively target Class I HDACs responsible for maintaining open chromatin structure in cancer cells. This selective inhibition achieves the desired gene expression modulation and anticancer activity while avoiding toxicity associated with broad-spectrum Class II HDAC inhibition
Data Source
AI summary
Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and/or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and/or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and/or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and/or cancers; and methods for inhibiting the growth, proliferation, and/or metastasis of a tumor and/or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.